Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:FTLFNASDAQ:GLSINASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.58+2.6%$1.44$0.91▼$6.69$132.26M2.162.59 million shs1.93 million shsFTLFFitLife Brands$14.42+0.8%$13.32$9.83▼$17.75$95.87M0.817,481 shs8,962 shsGLSIGreenwich LifeSciences$10.04+0.6%$10.57$8.06▼$18.75$133.27M1.7645,383 shs36,950 shsSCLXScilex$4.95+6.0%$8.77$3.60▼$80.50$34.45M1.0447,993 shs130,136 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+2.60%+18.80%+26.40%+11.27%-70.30%FTLFFitLife Brands+0.84%+8.34%+14.35%-8.07%+0.41%GLSIGreenwich LifeSciences+0.60%+7.49%-1.76%-23.53%-23.48%SCLXScilex+6.00%+5.32%-41.87%-68.37%-83.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine3.8941 of 5 stars3.13.00.04.21.41.71.3FTLFFitLife Brands4.1814 of 5 stars3.73.00.00.02.63.33.1GLSIGreenwich LifeSciences1.8444 of 5 stars3.50.00.00.02.43.30.0SCLXScilex3.1225 of 5 stars3.35.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.13Hold$6.54313.83% UpsideFTLFFitLife Brands 3.33Buy$20.5042.16% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00288.45% UpsideSCLXScilex 2.60Moderate Buy$455.009,091.92% UpsideCurrent Analyst Ratings BreakdownLatest SCLX, GLSI, FTLF, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/11/2025SCLXScilexD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$770.00 ➝ $630.003/17/2025FTLFFitLife BrandsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.002/28/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$770.00 ➝ $770.002/11/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M4.09N/AN/A$4.27 per share0.37FTLFFitLife Brands$64.47M2.06$0.76 per share19.05$3.04 per share4.74GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/ASCLXScilex$56.59M0.61N/AN/A($1.10) per share-4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)FTLFFitLife Brands$5.30M$0.8417.0713.11N/A13.38%28.03%15.13%N/AGLSIGreenwich LifeSciences-$8.89M-$1.20N/AN/AN/AN/A-185.12%-164.27%N/ASCLXScilex-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%5/12/2025 (Estimated)Latest SCLX, GLSI, FTLF, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025EDITEditas Medicine-$0.52N/AN/AN/A$0.79 millionN/A5/12/2025N/ASCLXScilex-$0.09N/AN/AN/A$17.79 millionN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75FTLFFitLife Brands0.281.500.64GLSIGreenwich LifeSciencesN/A6.916.91SCLXScilexN/A0.140.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FTLFFitLife Brands2.32%GLSIGreenwich LifeSciences4.16%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%FTLFFitLife Brands61.30%GLSIGreenwich LifeSciences51.67%SCLXScilex7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableFTLFFitLife Brands209.22 million3.56 millionNot OptionableGLSIGreenwich LifeSciences313.27 million6.35 millionNot OptionableSCLXScilex806.96 million222.07 millionOptionableSCLX, GLSI, FTLF, and EDIT HeadlinesRecent News About These CompaniesScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025April 22, 2025 | globenewswire.comScilex (NASDAQ:SCLX) Reaches New 1-Year Low - Should You Sell?April 19, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Trading Down 12.2% - Here's What HappenedApril 18, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Sees Large Volume Increase - Here's WhyApril 17, 2025 | marketbeat.comScilex Gets Orphan Drug Designation for Its Version of ColchicineApril 17, 2025 | marketwatch.comScilex treatment of pericarditis granted FDA orphan designationApril 17, 2025 | markets.businessinsider.comScilex confirms FDA awards orphan drug designation for colchicineApril 17, 2025 | markets.businessinsider.comScilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of PericarditisApril 16, 2025 | globenewswire.comScilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in CanadaApril 15, 2025 | globenewswire.comScilex announces 1-for-35 reverse stock splitApril 12, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Scilex Holding (SCLX)April 12, 2025 | msn.comScilex downgraded to Hold from Buy at D. Boral CapitalApril 11, 2025 | msn.comScilex Holding Company Announces 1-for-35 Reverse Stock SplitApril 11, 2025 | globenewswire.comD. Boral Capital Lowers Scilex (NASDAQ:SCLX) Price Target to $18.00April 4, 2025 | marketbeat.comScilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against AvevaMarch 26, 2025 | globenewswire.comScilex Holding Company Announces Change of Record Date for Preferred Stock DividendMarch 12, 2025 | nasdaq.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025March 10, 2025 | globenewswire.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025January 31, 2025 | globenewswire.comWhy Scilex Holding Co (SCLX) Stock is Currently 3.30% Above from Its 20-Day SMA?January 28, 2025 | bovnews.comScilex regains compliance with Nasdaq listing rulesJanuary 21, 2025 | markets.businessinsider.comScilex to file SNDA with FDA for ELYXYBJanuary 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, GLSI, FTLF, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$1.58 +0.04 (+2.60%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$1.57 -0.01 (-0.38%) As of 04/28/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.FitLife Brands NASDAQ:FTLF$14.42 +0.12 (+0.84%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$14.40 -0.03 (-0.17%) As of 04/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Greenwich LifeSciences NASDAQ:GLSI$10.04 +0.06 (+0.60%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$10.60 +0.57 (+5.63%) As of 04/28/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Scilex NASDAQ:SCLX$4.95 +0.28 (+6.00%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$5.21 +0.26 (+5.25%) As of 04/28/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
